2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
[HTML][HTML] Heart failure with preserved ejection fraction: JACC scientific statement
The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …
2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology …
MM Kittleson, GS Panjrath, K Amancherla… - Journal of the American …, 2023 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
[HTML][HTML] Heart failure with mid-range or mildly reduced ejection fraction
G Savarese, D Stolfo, G Sinagra, LH Lund - Nature Reviews Cardiology, 2022 - nature.com
Left ventricular ejection fraction (EF) remains the major parameter for diagnosis,
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …
Evaluation and management of heart failure with preserved ejection fraction
BA Borlaug - Nature Reviews Cardiology, 2020 - nature.com
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant
form of heart failure worldwide, in tandem with ageing of the general population and the …
form of heart failure worldwide, in tandem with ageing of the general population and the …
Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial
Background: Patients with heart failure with preserved ejection fraction have significant
impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin …
impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin …
From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited
WJ Paulus, MR Zile - Circulation research, 2021 - Am Heart Assoc
In accordance with the comorbidity-inflammation paradigm, comorbidities and especially
metabolic comorbidities are presumed to drive development and severity of heart failure with …
metabolic comorbidities are presumed to drive development and severity of heart failure with …